Product Name:

GSK3a-pY279


Product Number:

ab-pk882

Price:

Regular price
$98.00
Regular price
Sale price
$98.00

Download Product PDF

Target Full Name: Glycogen synthase-serine kinase 3 alpha

Target Alias: DKFZp686D0638; Factor A; Glycogen synthase kinase 3 alpha; GSK-3 alpha; GSK3-alpha; Kinase GSK3-alpha

Product Type Specific: GSK3a protein kinase phosphosite-specific antibody

Antibody Code: PK882

Antibody Target Type: Phosphosite-specific

Antibody Phosphosite: Y279

Protein UniProt: P49840

Protein SigNET: GSK3a

Antibody Type: Polyclonal

Antibody Host Species: Rabbit

Antibody Immunogen Source: Synthetic phosphopeptide patterned after human GSK3a

Antibody Immunogen Sequence: PNVS(pY)IAS(βA)C

Antibody Immunogen Description: Corresponds to amino acid residues P275 to S282 (C281A). Y279 phosphorylation stimulates phosphotransferase activity, promotes nuclear localization, and regulates cell growth, apoptosis, transcription, protein stability, and molecular association. This phosphosite is located in the kinase activation loop between catalytic subdomains VII and VIII. This is the major in vivo phosphorylation sites in GSK3a with ≥4312 mass spectrometry reports recorded in PhosphoSitePlus. GSK3a is known to be phosphorylated at this site in vitro by GSK3a, MEK1 (MAP2K1), and MEK2 (MAP2K2).

Production Method: The immunizing peptide was produced by solid phase synthesis on a multipep peptide synthesizer and purified by reverse-phase hplc chromatography. Purity was assessed by analytical hplc and the amino acid sequence confirmed by mass spectrometry analysis. This peptide was coupled to KLH prior to immunization into rabbits. New Zealand White rabbits were subcutaneously injected with KLH-coupled immunizing peptide every 4 weeks for 4 months. The sera from these animals was applied onto an agarose column to which the immunogen peptide was thio-linked. Antibody was eluted from the column with 0.1 M glycine, pH 2.5. Subsequently, the antibody solution was neutralized to pH 7.0 with saturated Tris.

Antibody Modification: Unconjugated. Contact KInexus if you are interest in having the antibody biotinylated or coupled with fluorescent dyes.

Antibody Concentration: 0.3 mg/ml

Storage Buffer: Phosphate buffered saline pH 7.4, 0.05% Thimerasol

Storage Conditions: For long term storage, keep frozen at -40°C or lower. Stock solution can be kept at +4°C for more than 3 months. Avoid repeated freeze-thaw cycles.

Product Use: Western blotting | Antibody microarray

Antibody Dilution Recommended: 2 µg/ml for immunoblotting

Antibody Species Reactivity: This antibody detects the target phosphoprotein in the following species due to conservation of amino acid sequence: Human | Chimpanzee | Rhesus Macaque | Rat | Mouse | Frog | Fruit fly.

Scientific Background: GSK3-alpha (GSK3a) is a protein-serine/threonine kinase of the CMGC group and GSK family. GSK3a features a 7-strand-barrel N-terminal domain, a central kinase domain, and a C-terminal domain, with the active site located between the N-terminal and alpha-helical domains. It is highly active following tyrosine phosphorylation within its activation T loop. Phosphorylation at Tyr-279 increases phosphotransferase activity and promotes nuclear localization. Phosphorylation at Ser-21 by Akt1 and other kinases inhibits phosphotransferase activity. GSK3a acts primarily as a negative regulator of glycogen synthesis and insulin signaling, while also playing a role in cell apoptosis and proliferation. It is also involved in the Wnt signaling pathway, regulating nuclear beta-catenin (phosphorylation triggers its degradation), and it regulates amyloid-beta production. It is widely expressed, especially in the brain and testis, and found in the cytoplasm and nucleus. GSK3a has been proposed as a tumour suppressor protein (TSP), since with loss of GSK3 there is an increase in WNT signalling, with beta-catenin stabilization, leading to tumorigenesis. GSK3a has also been proposed to act as an oncoprotein (OP), as acute leukemia required GSK3 for cell proliferation. In most human cancers, it is up-regulated in expression about 1.6-times the rate observed for most protein kinases. In addition to cancer, GSK3a has been implicated in a number of other diseases including Type II diabetes, Alzheimer’s (tau phosphorylation), Parkinson's, bipolar, and schizophrenia. This description may include information annotated by UniProt and/or Google AI.